Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > That was too easy, guess you missed it

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Jan 19, 2022 10:35am

86 Views

Post# 34332515

RE:That was too easy, guess you missed it

That was too easy, guess you missed it.

January 4 we were 'negotiating' for rights however, Jan.17 we announced that the negotiations are over and we "will enter into a new license agreement"

Is this not a material development?

"Claritas will enter into a new license agreement with Salzman Group for the development and commercialization of R-107 for the treatment of skin ulceration and wound healing, including the treatment of severe burns (the “License”)."

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market